AD_____

Award Number: DAMD17-99-1-9510

TITLE: Investigating the Use of the Prostate-Specific Membrane Antigen as a Receptor for Retroviral Gene-Transfer Agents

PRINCIPAL INVESTIGATOR: Mark W. Pandori, Ph.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215

REPORT DATE: July 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020913 032

# REPORT DOCUMENTATION PAGE

*Form Approved*
*OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

| 1. AGENCY USE ONLY (Leave blank) | 2. REPORT DATE | 3. REPORT TYPE AND DATES COVERED |
|---|---|---|
| | July 2001 | Annual Summary (1 Jul 00 - 30 Jun 01) |

**4. TITLE AND SUBTITLE**
Investigating the Use of the Prostate-Specific Membrane Antigen as a Receptor for Retroviral Gene-Transfer Agents

**5. FUNDING NUMBERS**
DAMD17-99-1-9510

**6. AUTHOR(S)**
Mark W. Pandori, Ph.D.

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215

E-Mail: mpandori@caregroup.harvard.edu

**8. PERFORMING ORGANIZATION REPORT NUMBER**

**9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**10. SPONSORING / MONITORING AGENCY REPORT NUMBER**

**11. SUPPLEMENTARY NOTES**
Report contains color.

**12a. DISTRIBUTION / AVAILABILITY STATEMENT**
Approved for Public Release; Distribution Unlimited

**12b. DISTRIBUTION CODE**

**13. ABSTRACT** ***(Maximum 200 Words)***

The goal of this proposal is to attempt a novel strategy for the use of viruses in the delivery of anti-cancer genes to prostate cancer cells. Current methods involving the use of viruses to deliver therapeutic genes for the treatment of any disease are hindered by the inability to target viral agents specifically to diseased tissue or organs. Recently, a protein marker has been characterized on the surface of prostate cancer cells. This marker, called the prostate-specific membrane antigen (PSMA), is readily detectable on prostate cancer cells from a large percentage of patients with prostate cancer. The abundance of this marker on cancerous prostate cells allows such cells to be detected and discriminated from both normal prostate cells and the cells of other bodily tissues. We have sought to analyze the possibility of utilizing the PSMA on the surface of prostate cancer cells as a way to target viral gene therapy agents specifically to tumors of the prostate.

| 14. SUBJECT TERMS | 15. NUMBER OF PAGES |
|---|---|
| Prostate, PSMA, Retrovirus, Streptavidin, biotin | 46 |
| | 16. PRICE CODE |

| 17. SECURITY CLASSIFICATION OF REPORT | 18. SECURITY CLASSIFICATION OF THIS PAGE | 19. SECURITY CLASSIFICATION OF ABSTRACT | 20. LIMITATION OF ABSTRACT |
|---|---|---|---|
| Unclassified | Unclassified | Unclassified | Unlimited |

## Table of Contents

## Introduction

The goal of this proposal is to attempt a novel strategy for the use of viruses in the delivery of anti-cancer genes to prostate cancer cells. Current methods involving the use of viruses to deliver therapeutic genes for the treatment of any disease are hindered by the inability to target viral agents specifically to diseased tissue or organs. Recently, a protein marker has been characterized on the surface of prostate cancer cells. This marker, called the prostate-specific membrane antigen (PSMA), is readily detectable on prostate cancer cells from a large percentage of patients with prostate cancer. The abundance of this marker on cancerous prostate cells allows such cells to be detected and discriminated from both normal prostate cells and the cells of other bodily tissues. We have sought to analyze the possibility of utilizing the PSMA on the surface of prostate cancer cells as a way to target viral gene therapy agents specifically to tumors of the prostate.

## Annual (Final) Summary

The second and final year of the two year fellowship has come to completion. Since the end of the first year, we have made tremendous progress toward accomplishing our goal of creating a PSMA-specific viral delivery system. In order to accomplish our initaial goals, we have had to make significant modifications to the original proposed plan. However, we have found that these modifications have resulted in the creation of a potentially powerful technology to aid in the targeting of any type of virus particle to any area of interest. We have applied this new technology to the targeting of PSMA-overexpressing cells, and have succeeded in attaining our originally stated aims.

The initial Statement of Work described a plan whereby antibodies against prostate cancer cells would be placed on the surface of retroviral particles (Spleen necrosis virus and ecotropic murine leukemia virus). Placement of these antibodies was postulated to result in cell-type specific infection of prostate cancer cells. The attachment chemistry that was proposed to be used involved the attachment of biotinylated antibodies to streptavidin, which is tetrameric. The streptavidin would then function as a bridge, connecting the antibody to a biotinylated virus particle. All of this proposed work has been carried out, however a major modification made has been the type of biotin molecule used on the surface of viral particles. Initial experiments, described in the first Annual Summary, showed that biotinylation of viral particles resulted in a decrease in viral infectivity. Noting this, we sought to discover whether by using a photocleavable variety of biotin (commercially available through Pierce Chemicals), we would be able to

restore infectivity to biotinylated particles by simply exposing the particles to 365 nm light. In principle, we sought to determine whether we could create viruses whose infectivity could be shut-off by biotinylation, but restored only when and where the virus was exposed to light (365 nm)-hence creating photoactivatable viral vectors. As shown in the Appendix, this strategy worked extremely well with amphotropic retroviral particles, and resulted in the publication of this technique in the journal Gene Therapy.

Subsequent to the creation of photoactivatable viral particles. We applied this novel technique to Adenoviral particles, which we felt possessed higher biochemical stability and would perhaps be more amenable to surface chemical modifications then retroviruses. This strategy of photoactivation of viral infectivity worked very well also with adenoviral particles, indicating that this novel technique possessed versatility. Utilizing these photoactivatable adenoviral vectors, we were able to demonstrate photo-specific infection of a subcutaneous tumor in a mouse model, simply by irradiating through the skin with intense 365 nm light (see Appendix).

Having created this novel technology, we then decided to go back to the original Statement of Work and determine whether this strategy could be applied and refined to allow for the specific infection of PSMA-overexpressing cells. To accomplish this, we took advantage of the fact that the inactivation of viral infectivity described above was based on over-biotinylation of viral particles. Hence, these inactivated particles, as postulated in the original Statement of Work, should be capable of binding to streptavidin and further, a biotinylated antibody against PSMA.

We have tested the feasibility of this approach by asking whether photocleavable biotin (PC-biotin)-modified viral vectors, with biotinylated anti-PSMA antibodies, could be used to infect

PSMA-expressing cells *in vitro* . To attempt this, we used a stepwise format, in lieu of pre-conjugation of PC-biotin-modified viral vectors with biotinylated anti-PSMA antibodies. D-17 osteosarcoma cells, engineered to over-express human PSMA ($D\text{-}17_{P4}$), were grown in monolayers. $D\text{-}17_{P4}$ cells were exposed to excess amounts of either biotinylated monoclonal anti-PSMA antibody J591 or biotinylated non-specific $IgG_{2b}$ at 4 °C for 1 hr. Following removal of the cell supernatant and washing, cells were exposed to excess Neutralite Avidin (Pierce) for 30 min at 4 °C. Cells were then exposed to PC-biotin-modified adenoviral vectors for 1 hr. Cells were washed and exposed to 365-nm light for 4 min, whereupon they were cultured at 37 °C for 48 hr. Cells were analyzed for the expression of the *lacZ* gene (Fig. 2). $D\text{-}17_{P4}$ cells that had been treated with anti-PSMA antibody J591 showed far greater amounts of infection than $D\text{-}17_{P4}$ cells treated with non-specific $IgG_{2b}$. As expected, there was a very limited amount of infection when no photo-irradiation was applied. For similarly treated D-17 cells, which do not express PSMA, there was no observable difference in the amount of infection between the two antibody species used.

In principle, the major goal of our original proposal has been met. We have successfully generated a PSMA-specific delivery system for viral particles. A vast majority of our originally proposed strategy remained intact through the conclusion of this work (the use of biotin and stretptavidin and biotinylated antibodies). Notably however, we have not utilized the original proposed strategy of modifying the tropism of spleen necrosis or ecotropic murine leukemia viruses. We feel however, that the development of photoactivatable viral vectors has resulted in a far greater contribution to the field of gene therapy in general. Additionally, this technique is highly versatile, and with some relatively simple modfications, may be applicable readily in a clinical setting.

The work accomplished as a result of this fellowship has resulted in 2 manuscripts (one published, (Gene Therapy) and one in review), and two news articles on its behalf: one published in Nature Medicine, and one in the journal Biophotonics (see appendix).

**Fig. 1 Targeting of photo-activatable adenoviral vectors to PSMA, expressed on target cancer cells**, using anti-PSMA antibodies. D-$17_{P4}$ is a derivative of D-17 osteosarcoma cells, engineered to over-express PSMA. J591, a monoclonal antibody against the extracellular domain of PSMA; anti-NSP, non-specific $IgG_{2b}$. Dark, no irradiation; Light, irradiated with 365-nm light.



## Key Accomplishments

- The construction of biotinylated retroviral gene delivery agents; demonstration of the amounts of biotin which result in maximal biotin incorporation with minimal effects on virion infectivity

- The attachment of streptavidin to the surface of retroviral gene delivery agents; accomplished in either of two ways: by the addition of streptavidin to biotinylated and purified viral particles, or by the use of streptavidin hydrazide

- Demonstration of the use of hydrazide-modified streptavidin as a means of attaching streptavidin molecules to the surfaces of retroviral particles

- The construction of streptavidin-hydrazide-anti-PSMA fusions by chemical means which are covalent and do not involve biotin-streptavidin interactions

- The construction of a binary system of cell lines which either over-express or do not express PSMA, for the anaylsis of any PSMA-specific targeting system

- The creation of an infectivity "switch" whereby the infectivity of viral particles is inactivated, only to be reactivated in the presence of 365 nm light. This allows for the control of the timing and location of viral infections

- The use of photoactivatable viral vectors in the specific infection of cells which overexpress the Prostate-specific membrane antigen (PSMA)

- The use of photoactivatable viral vectors to infect specifically, a tumor, in a light-dependent manner, in a mouse model

**Reportable Outcomes:**

1. Publication in Gene Therapy, 2001 **7**, pp. 1999-2006
2. Manuscript submitted to PNAS, May 2001
3. News article, Nature Medicine, January 2001
4. News article, Biophotonics, May 2001

Gene Therapy (2000) 7, 1999–2006
© 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00
www.nature.com/gt

***VIRAL TRANSFER TECHNOLOGY*** ***RESEARCH ARTICLE***

# *Photoactivatable retroviral vectors: a strategy for targeted gene delivery*

MW Pandori and T Sano

*The Center for Molecular Imaging Diagnosis and Therapy and Basic Science Laboratory, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA*

*We have explored a novel strategy for the targeting of retroviral vectors to particular sites or cell types. This strategy involves a method whereby the infectivity of a retroviral vector is neutralized by treatment of viral particles with a photocleavable, biotinylation reagent. These modified viral vectors possess little to no infectivity for target cells. Exposure of these modified viral vectors to long-wavelength UV light induces a reversal of the neutralizing, chemical modification resulting in restoration of infectivity to the viral vector. This infectivity 'trigger' possesses great potential, both as a research tool and as a novel tactic for the targeting of gene-transfer agents, since it would become possible to direct both the time and location of a viral infection in a versatile manner.* Gene Therapy (2000) **7,** 1999–2006.

**Keywords:** *retrovirus; biotin; photocleavable; gene therapy*

## *Introduction*

There has been considerable success in the construction of highly infectious amphotropic viral gene transfer vectors. Retroviral vectors possessing either the murine amphotropic envelope glycoprotein or the envelope glycoprotein G of vesicular stomatitis virus (VSV-G), in addition to those vectors based on either adeno-associated virus (AAV) or adenoviruses have been generated which possess transduction efficiencies of $10^8$ infectious units/ml and greater. The high transduction efficiencies of these viral vectors make them ideal for use both as research tools and as *ex vivo* gene transfer reagents for gene therapy procedures. However, the *in vivo* use of such vectors is restricted because of the broad tropism that these viruses possess.[1,2]

A major challenge, for the use of viruses and viral vectors as biologically useful tools continues to be the ability to target virus-mediated gene transduction to particular areas or cell types of interest. Much of the effort to construct viral vectors with targetable infectivity has involved the genetic modification of viral envelope glycoproteins, most commonly through the fusion of such proteins with binding reagents for particular cell types, such as single-chain antibodies, peptides, and ligands that can bind to cell-surface molecules.[3–5] Largely, this strategy has proven both unsuccessful and difficult. The genetic manipulation of all retroviral envelope glycoproteins tested thus far has shown that these glycoproteins are highly sensitive to alteration. Fusions of retroviral envelope glycoproteins with a variety of protein species have resulted in the generation of unstable, incorrectly folded, or non-functional proteins. In some cases, targetability to particular cell types was accomplished, but the resulting viral vectors showed markedly reduced transduction efficiencies.

Here, we describe an alternative strategy for the targeting of the infectivity of viral vectors. This strategy uses retroviral vectors, the infectivity of which is inhibited by a chemical modification that can be reversed upon exposure to light of a specific wavelength.

## *Results*

We have explored an alternative strategy for the targeting of viral vectors to particular cell types or sites. This strategy involves a method whereby the infectivity of a viral vector is neutralized by a reversible chemical modification (Figure 1). Such chemically modified viral vectors possess little to no infectivity for potential target cells until an external stimulus is applied. This external stimulus induces a reversal of the neutralizing, chemical modification resulting in a restoration of infectivity to the viral vector. Such an infectivity trigger would possess great potential, as both a research tool and a targetable gene transfer agent, as it would become possible to direct both the time and location of a viral infection in a versatile manner. To test if this strategy can be employed to control the infectivity of retroviral vectors, we used a Moloney murine leukemia virus (MLV)-derived vector. This vector, termed Tel-Ampho, bears the envelope glycoprotein of the 4070A amphotropic murine retrovirus and packages a transducable, bacterial *lacZ* gene allowing for the easy identification and quantification of infected cells.[6] We tested NHS-PC-LC-Biotin as a modification reagent for the control of infectivity of Tel-Ampho. NHS-PC-LC-Biotin is a biotin derivative containing an *N*-hydroxysuccinimide ester (NHS) which reacts with primary amino groups by nucleophilic attack. This allows for simple attachment of the biotin moiety to the N-ter-

*Correspondence: T Sano*
Received 23 May 2000; accepted 14 September 2000




*Figure 1* *Concept of inactivation and subsequent reactivation of the infectivity of viral vectors using an inactivating reagent and an external (reactivating) stimulus.*

mini and lysine residues of protein molecules. This biotin derivative also contains a photocleavable, 1-(2-nitrophenyl)ethyl moiety, which exhibits efficient cleavage upon exposure to light of wavelengths between 300 and 365 nm. Exposure of proteins, conjugated with NHS-PC-LC-Biotin to 300–365 nm light results in the release of the biotin moieties from the proteins, the conjugation sites (primary amino groups) of which are restored to their original, unmodified form.[7]

Treatment of Tel-Ampho with NHS-PC-LC-Biotin at concentrations of 2.5 and 5 mg/ml, greatly reduced the infectivity of this viral vector (Figure 2a). In some cases, at these concentrations, the infectivity of Tel-Ampho was completely eliminated. The presence of biotinylation reagent on viral vector components was implied by the marked effect of the reagent on the infectivity of Tel-Ampho. To confirm that the inhibition of infectivity caused by the treatment of NHS-PC-LC-Biotin was due to conjugation of this reagent to virions, and not to the presence of unreacted reagent, Tel-Ampho reacted with NHS-PC-LC-Biotin was combined with excess glycine that efficiently reacts with unreacted NHS-PC-LC-Biotin. Additionally, this post-conjugation treatment with excess glycine was also performed after the removal of unreacted NHS-PC-LC-Biotin from viral vectors by several rounds of ultrafiltration. However, neither of these treatments showed any effect on the infectivity inhibition of Tel-Ampho by treatment with NHS-PC-LC-Biotin. These results, along with the fact that the NHS moiety of NHS-PC-LC-Biotin undergoes rapid hydrolysis in aqueous media[8,9] suggest that the infectivity inhibition of Tel-Ampho by NHS-PC-LC-Biotin is caused by conjugation of the biotinylation reagent to viral vectors.

We next tested if the infectivity of Tel-Ampho, which has been inhibited by treatment of NHS-PC-LC-Biotin, could be restored by exposure to 365 nm light. This wavelength of light can cleave NHS-PC-LC-Biotin away from proteins to which it has been conjugated and would cause minimal damage to retroviral particles. Because photocleavage of this reagent results in the original target molecule being restored to its unmodified form, we reasoned that exposure of retroviral vectors treated with NHS-PC-LC-Biotin might regain their infectivity. We treated three different stocks of Tel-Ampho with 2.5 mg/ml NHS-PC-LC-Biotin, which resulted in nearly complete inhibition of their infectivity. These retroviral vectors were then exposed to 365 nm light and at regular intervals, samples of these treated stocks were collected and analyzed for their ability to infect target cells (Figure 2b). Each of the biotinylated Tel-Ampho stocks showed demonstrative gains in infectivity upon exposure to 365 nm light. Restoration of infectivity occurred within 4–6 min of irradiation. As shown for stock 3, irradiation of biotinylated viral vector resulted in nearly complete restoration of the infectious potential for the viral vector stock. Exposure of viral vectors to 365 nm light for longer than 8 min had a detrimental effect on viral infectivity. This might be caused by the damage of viral components by shorter-wavelength UV light that would also be emitted by the light source used. These data indicate that the inhibition of infectivity caused by the reaction of Tel-Ampho vectors with NHS-PC-LC-Biotin can be reversed upon exposure of these biotinylated, inactivated retroviral vectors to 365 nm light. These data indicate that these retroviral vectors, when treated with NHS-PC-LC-Biotin, possess light-activatable infectivity. A series of experiments showed that the infectivity of Tel-Ampho was restored to 30–90% of the original infectivity upon photo-irradiation.

We next sought to determine whether activation of retroviral vectors could be performed within the context of virus target cells. To investigate this, Tel-Ampho was treated with 2.5 mg/ml NHS-PC-LC-Biotin as described earlier. Equal amounts of biotinylated Tel-Ampho were

then added to cultures of D-17 cells,[10] followed by either irradiation with 365 nm light for 5 min or placement in the dark. As shown in Figure 3, target cells mixed with biotinylated and nonirradiated viral vectors showed little or no infection. In contrast, those mixtures of viral vectors and cells that had been exposed to 365 nm light showed considerable infection of target cells. No detectable difference in cell viability or growth rate[c] was observed between the irradiated and nonirradiated cultures, indicating that neither the exposure of long-wavelength UV light nor unreacted biotinylation reagent, if present, had any effect on cell growth or viability. These data demonstrate that the infectivity of these viral vectors can be activated *in situ*. This offers the potential for the use of this strategy to target viral vector infection at a location of interest by using focused light.

To determine which viral components were biotinylated by treatment with NHS-PC-LC-Biotin, we analyzed biotinylated, inactivated Tel-Ampho using Western blotting analysis. Concentrated Tel-Ampho was treated with 2.5 mg/ml NHS-PC-LC-Biotin as above. The resulting Tel-Ampho samples were subject to gel filtration chromatography using Sephacryl S-1000 followed by passage through a 0.45-μm filter and subsequent centrifugation (to purify virions from other materials).[11] The resulting viral vectors were either irradiated with 365 nm light or kept in a dark place before the separation of viral components by SDS-PAGE.[12] Biotinylated viral components were identified by using a streptavidin-peroxidase conjugate as a probe after transfer to PVDF membrane (Figure 4a). Biotinylated proteins are found at approximately 150, 30, 25 and 15 kDa on the blot (lane B). The molecular masses of these protein species suggest that they are the *gag-pol* and *gag* protein products of MLV.[13] This is supported by the fact that these biotinylated viral components comigrate with proteins that are immunoreactive with polyclonal antibody against disrupted murine leukemia virus particles (lane A). In contrast, the Tel-Ampho that was treated with NHS-PC-LC-Biotin and subsequently subjected to irradiation with 365 nm light shows markedly less binding by the streptavidin-peroxidase conjugate (lane C). In particular, the viral components of approximately 150, 25 and 15 kDa, seen in nonirradiated Tel-Ampho (lane B), are absent in the lane containing an equal amount of irradiated virus (lane C). However, a biotinylated viral component of approximately 30 kDa remains readily detectable, although the signal intensity is reduced. This indicates that removal of NHS-PC-LC-Biotin from this viral component did not occur to completion under the exposure conditions used. From its molecular mass, this protein species is the core (*gag*) antigen of MLV. The location of this protein in virions at the viral core may render it less susceptible to photon irradiation, compared with matrix (p15) or *gag-pol* (approximately 200 kDa) components, which are membrane-associated and thus should be readily access-




*Figure 2 (a) Effect of treatment with NHS-PC-LC-Biotin on the infectivity of Tel-Ampho. Serial dilutions of 25 mg/ml NHS-PC-LC-Biotin were made in dimethylformamide (DMF) and were allowed to react with aliquots (200 μl) of Tel-Ampho for 150 min before halting the reaction and was followed by viral infectivity assay (as described in Materials and methods). DMF was found to have no effect on virion infectivity at dosages up to 30% (data not shown). Data shown are the average of two experiments and is representative of at least three independent experiments. (b) Time course of the restoration of viral infectivity to biotinylated, inactivated Tel-Ampho upon exposure to long-wavelength (365 nm) UV light. Tel-Ampho (200 μl) was treated with 2.5 mg/ml NHS-PC-LC-Biotin for 150 min on ice as in panel a. Treated viral stocks were placed in borosilicate glass vials and subjected to irradiation with long-wavelength (365 nm) UV light (at a distance of 0.5 cm, utilizing a UVL-21 lamp, intensity of 720 μW/cm² at 15 cm distance) (UV Products). At the intervals shown, samples (10 μl) of viral vectors were removed from vials and placed over monolayers of D-17 cells for infectivity analysis. ○, Stock 1, biotinylated, irradiated; □, stock 2, biotinylated, irradiated; +, stock 3, biotinylated, irradiated; ◆, stock 3, not biotinylated, irradiated; ▽, stock 3, biotinylated, not irradiated.*




*Figure 3 Light-activated infection of D-17 cells. Tel-Ampho (50 μl), concentrated as described in Materials and methods and subsequently treated with 2.5 mg/ml NHS-PC-LC-Biotin for 150 min, was placed within each of six 35-mm culture dishes containing monolayers of D-17 cells ($2 \times 10^5$/dish) covered with 500 μl of DMEM/10% FBS supplemented with 5 μg/ml polybrene. Three of the dishes were placed on ice in a dark box, while the remaining three dishes were placed on ice and exposed to 365 nm light. Exposure was from the top of open culture dishes and was performed for 6 min at a distance of 2 cm between the source (UVL-21 lamp) and the monolayer of cells. Exposure was for 6 min. At 48 h after irradiation, cells were then subjected to infectivity assays, as described in Materials and methods.*

ible to light. These data suggest that biotinylation of the core *gag* antigen is not the cause of infectivity inhibition by treatment with NHS-PC-LC-Biotin. Also notable is the apparent lack of detectable signal for the gene products of *env* (80 kDa) and *pol* (80 kDa). This may be caused by the lack of sensitivity in this analysis, since these viral components exist in much smaller amounts than the *gag* gene products in mature virion particles.[13] Thus, from this analysis, we are unable to determine whether or not the gene products of *env* and *pol* are biotinylated by treatment with NHS-PC-LC-Biotin.

The effect of biotinylation on the reverse transcriptase (RT) (a *pol* gene product) activity of Tel-Ampho particles was determined by RT assays. Tel-Ampho was treated with NHS-PC-LC-Biotin and divided into two samples, one irradiated with 365 nm light and the other kept in the dark. RT assays on these samples after disruption of virions (Figure 4b) show that biotinylation of Tel-Ampho with NHS-PC-LC-Biotin resulted in an approximate 50% decrease in RT activity. However, exposure of the biotinylated Tel-Ampho to 365 nm light had no significant effect on the RT activity. These data indicate that the RT activity was reduced by treatment of Tel-Ampho, suggesting biotinylation of virion-associated RT. However, because the reduction of RT activity caused by NHS-PC-LC-Biotin was not restored by irradiation, it is unlikely that modulation of RT activity can account for the infectivity inhibition by biotinylation and its restoration upon light irradiation.

Although the biotinylation of the *env* gene product was not apparent by Western blotting analysis (Figure 4a), it remains possible that this viral component was modified by biotinylation. To assess whether the envelope glycoprotein of Tel-Ampho was affected by biotinylation, a viral interference assay was performed. This assay is designed to assess the ability of a set of viral particles to inhibit the binding and entry of another set of viral particles by competing for interaction with the cell-surface receptors used for viral infection. First, the ability of this assay to assess the function of the *env* gene product was determined. Tel-Ampho vector was concentrated and subsequently inactivated by a psoralen derivative, 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT), and exposure to long-wavelength UV light. Inactivation of Tel-Ampho by the psoralen derivative is caused by cross-linking of the viral RNA genomes and has no significant effect on other properties of the viral vectors, including the binding to target cells.[14–16] These psoralen-inactivated Tel-Ampho particles were mixed with unmodified Tel-Ampho vector to see if they can inhibit the infectivity of unaltered Tel-Ampho for target cells. Psoralen-inactivated Tel-Ampho, when in a ratio of approximately 20:1 with unaltered Tel-Ampho, strongly inhibited infection of target cells by the unaltered Tel-Ampho (Figure 4c). Identical viral cores which display the envelope glycoprotein of spleen necrosis virus (SNV), Tel-SNV, were tested in the same manner. The psoralen-inactivated Tel-SNV was markedly ineffectual relative to psoralen-inactivated Tel-Ampho in inhibiting the infection of target cells by unaltered Tel-Ampho. These results indicate that the inhibition of Tel-Ampho infection by psoralen-inactivated Tel-Ampho was caused primarily by inhibition of the ability of the *env* gene product to mediate the binding and/or entry to target cells.

Tel-Ampho was inactivated by psoralen treatment as above, and then biotinylated with NHS-PC-LC-Biotin. The resulting psoralen-inactivated, biotinylated Tel-Ampho was tested for the ability to inhibit the infection of target cells by unaltered Tel-Ampho. The psoralen-inactivated, biotinylated Tel-Ampho was demonstrably less effective than psoralen-inactivated, nonbiotinylated Tel-Ampho in blocking the infection of target cells by unaltered Tel-Ampho. When $10^4$ target cells were used, psoralen-inactivated, biotinylated Tel-Ampho was approximately 45-fold less effective at inhibiting the infectivity of unaltered Tel-Ampho than their inactivated, nonbiotinylated counterpart. These data imply that biotinylation of Tel-Ampho with NHS-PC-LC-Biotin results in a loss of the function of the envelope glycoprotein. Therefore, it is possible that the infectivity inhibition caused by NHS-PC-LC-Biotin treatment is due to the inability of biotinylated viral vectors to bind to and/or to enter target cells. The possibility of this as a mechanism of infectivity inhibition is supported by the observation that a similar biotinylation reagent, which is charged and highly water-soluble (sulfo-NHS-LC-Biotin; Pierce Chemical), inactivated the infectivity of Tel-Ampho at identical concentrations as NHS-PC-LC-Biotin (data not shown). This water-soluble biotinylation reagent is incapable of pass-




*Figure 4* *(a) Western blotting analysis of biotinylated, purified Tel-Ampho. Lane A, Western blot of lysed Tel-Ampho, detected with polyclonal antiserum raised against disrupted MLV. The data shown are representative of two experiments. (b) Effect of biotinylation on reverse transcriptase activity of Tel-Ampho. (c) Analysis of the effect of biotinylation on the function of the env gene product using a viral interference assay. A, Tel-Ampho with psoralen-inactivated Tel-Ampho; B, Tel-Ampho with psoralen-inactivated Tel-SNV; C, Tel-Ampho with psoralen-inactivated, biotinylated Tel-Ampho. (d) Comparison of Tel-Ampho with Tel-SNV for use as light-activatable viral vectors. A, Tel-Ampho, biotinylated with 2.5 mg/ml NHS-PC-LC-biotin, stored in the dark; B, Tel-Ampho, biotinylated as A, and subsequently exposed to 365 nm light for 3 min; C, Tel-Ampho, treated with an equivalent amount of DMF as in A and B (with no biotinylation reagent), stored in the dark; D, Tel-SNV, biotinylated as A, stored in the dark; E, Tel-SNV, biotinylated as D, and subsequently exposed to 365 nm light for 3 min; F, Tel-SNV, treated with an equivalent amount of DMF as D and E (no biotinylation reagent), stored in the dark. Data shown are representative of two independent experiments.*

ing through lipid bilayers.[17] Hence, it should biotinylate only the outer surface of (enveloped) retroviral particles.

Also supporting the role of the envelope glycoprotein in biotinylation-mediated inactivation of infectivity is the observation that Tel-SNV (which is otherwise identical to Tel-Ampho except that it bears the envelope glycoprotein of SNV instead of that of amphotropic MLV) showed a behavior very different from Tel-Ampho when treated with NHS-PC-LC-Biotin. While the infectivity of Tel-SNV was effectively inactivated by treatment with NHS-PC-LC-Biotin, exposure of the resulting biotinylated Tel-SNV with 365 nm light did not restore viral infectivity (Figure 4d). Because the only difference between the Tel-Ampho and Tel-SNV particles is the type of envelope glycoprotein displayed, it is implied that the phenomenon of light-facilitated infectivity activation involves the inactivation and subsequent reactivation of the function of the viral envelope glycoprotein.

## Discussion

Here we have demonstrated the potential for the creation of viral vectors with externally activatable infectivity. Using a photocleavable reagent and simple procedures, the infectivity of an amphotropic retroviral vector species can be nearly or completely eliminated. Upon exposure of these viral vectors to light, infectivity was restored to these viral vectors. This strategy of activatable infectivity worked in either the presence or absence of viral target cells, demonstrating its ability to provide effective control over the transduction of genes by amphotropic viral vectors. Possible applications of viral vectors with activatable infectivity are numerous. For example, the infectivity of amphotropic vectors, normally not targetable due to the lack of tissue or cell-type specificity, could conceivably be activated within specific areas by a directed, focused application of light. Because treatment with NHS-PC-LC-Biotin results in the attachment biotin moieties to retroviral vectors, it may be possible to conjugate biotin-binding proteins, such as avidin and streptavidin to these biotinylated and inactivated vectors. Streptavidin could function as a bridge to conjugate a variety of targeting reagents, such as single-chain antibodies against cell-surface molecules of target cells, to the surface of biotinylated and inactivated viral vectors. Retroviral vectors with activatable infectivity may also be useful as a research tool, where either temporal or spatial control of an infection is desired. Additionally, the ability to switch infectivity off or on might be desirable for safe handling of highly contagious or dangerous pathogens. The transportation of such pathogens might also be made safer if their infectivity could be inactivated before transport, to be restored upon reception.

We are finding that a number of human cell lines behave similarly to the D-17 line (data not shown). However, the current treatment concentration (2.5 mg/ml) of NHS-PC-LC-Biotin resulted in varied levels of inactivation from cell line to cell line. This suggests that optimization of treatment conditions may be required for each cell type in question.

## Materials and methods

### Cell lines and virus production

The dog osteosarcoma cell line, D-17 (10) (American Type Culture Collection, Manassas, VA, USA) was maintained in Dulbecco's modified Eagle's medium (DMEM; Cellgro, Herndon, VA, USA) supplemented with 6% fetal bovine serum and penicillin-streptomycin. A human rhabdomyosarcoma cell line, TelCeB6,[3] was maintained in DMEM supplemented with 10% FBS and penicillin-streptomycin.

For production of retroviral stocks bearing the amphotropic envelope from 4070A murine leukemia virus (Tel-Ampho), TelCeB6 cells ($10^7$) were cultured overnight in 150-mm culture dishes. These cells produce murine leukemia virus particles that possess *gag* and *pol* gene products, but lack envelope glycoprotein. Cells were transfected by the calcium-phosphate method with 20 μg of the plasmid, pA,[3] which expresses the amphotropic envelope glycoprotein of 4070A murine leukemia virus. After transfection (72 h), culture media containing Tel-Ampho retroviral vectors were collected, and centrifuged at 4000 *g* for 10 min. Supernatants were then divided into aliquots and stored at –70°C. Production of retroviral vectors bearing the spleen necrosis virus (SNV) envelope glycoprotein was accomplished by the method described above, using a plasmid, pRD134, that efficiently expresses the envelope glycoprotein of SNV.[5]

### Infectivity assays

To determine the infectivities of retroviral vectors, virus particles were placed over monolayers of D-17 cells (10 000 per well, in a 96-well plate, or 40 000 per well in a 24-well plate) in a total volume of 100 μl or 200 μl, respectively, of DMEM/10% FBS containing 5 μg/ml polybrene. After exposure of retroviral vectors to D-17 cells (48 h), cells were fixed in 0.5% paraformaldehyde and stained for the expression of *lac*Z gene using 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) as the substrate. Infected (*lac*Z-expressing) cells, which possessed easily identifiable blue nuclei, were counted under a light microscope.

### Biotinylation of viral vectors and light exposure of biotinylated viral vectors

Serial dilutions of 25 mg/ml NHS-PC-LC-Biotin (Pierce Chemical, Rockford, IL, USA) were made in dimethylformamide (DMF). Dilutions of NHS-PC-LC-Biotin were added to aliquots (200 μl) of Tel-Ampho stock solutions, and the final concentration of DMF in each treated vector stock was adjusted to 10% (v/v). NHS-PC-LC-Biotin and Tel-Ampho mixtures were placed on ice and allowed to react in the dark for 150 min. Reactions were terminated by the addition of 200 μl of 100 mM glycine/PBS (pH 7.4) and 200 μl of DMEM containing 10% FBS and 30 min of storage at 4°C. Samples of NHS-PC-LC-Biotin-treated viral vectors (10 μl) were then placed over monolayers of D-17 (10 000 per well in a 96-well plate) and subject to infectivity assays.

For analysis of the time-course of biotinylated virion infectivity *versus* irradiation with long-wavelength UV light, a Tel-Ampho stock solution (2 ml) was subject to ultrafiltration to a final volume of 200 μl using filtration devices (YM-100, Millipore, Bedford, MA, USA) with a molecular mass cut-off of 100 kDa. This was followed by dilution of the concentrated viral vector with PBS (pH 7.4) to a volume of 2 ml. This process was repeated, and the resulting viral vector stock was concentrated to a volume of 200 μl by ultrafiltration. Concentrated viral vectors were then treated with 2.5 mg/ml NHS-PC-LC-Biotin for 150 min on ice. Treated viral stocks were placed in borosilicate glass vials and subject to irradiation with long wavelength (365 nm) UV light at a distance of 0.5 cm, utilizing a UVL-21 lamp (720 μW/cm² at 15 cm distance) (UV Products, Upland, CA, USA). At the intervals shown, samples (10 μl) of virus were removed from vials and subjected to infectivity assays, as described above.

### Western blotting analysis

Tel-Ampho (3 ml) was filtered by passage through a 0.45-μm filter. Filtered viral vector was centrifuged at 8000 *g* for 10 min at 4°C. The supernatants were concentrated to a volume of 200 μl by YM-100 ultrafiltration (100 kDa molecular mass cut-off). Viral vectors were treated with 2.5 mg/ml NHS-PC-LC-Biotin/10% DMF for 150 min on ice in the dark. An equal volume of 100 mM glycine/PBS (pH 7.4) was added to the biotinylated viral vectors, and the mixture was placed on ice, in the dark for 30 min.

The treated viral vectors were subjected to ultrafiltration to reduce the volume to 200 μl. This concentrated, biotinylated viral vector was placed in a 2.5-ml (7.5-cm length) Sephacryl S-1000 gel filtration chromatography column. Viral vectors were eluted with PBS (pH 7.4), and fractions from 400 μl to 1500 μl were collected (determined to be the virus-containing fractions). Purified viral vector (500 μl) was stored in the dark at room temperature or exposed to irradiation by 365-nm light for 6 min at a distance of 0.5 cm (as described above). These viral vectors were centrifuged at 24 000 *g* at 4°C for 2 h to pellet the viral vector particles. Pelleted viral vectors were suspended in 15 μl of an SDS-containing sample buffer and subjected to SDS-PAGE[12] using 10–20% polyacrylamide gradient gels. Proteins were blotted on PVDF membrane that was then blocked with SuperBlock (Pierce). Blots were incubated for 1 h in a 1/10 000 dilution of a streptavidin-peroxidase conjugate (Pierce) in SuperBlock containing 0.02% Tween 20. Binding of the streptavidin-peroxidase conjugate was detected by using an enhanced chemiluminescence (ECL) kit (Amersham, Piscataway, NJ, USA). To detect all viral components on blots, Tel-Ampho (1 ml) were subjected to ultrafiltration using a YM-100 filtration unit to a final volume of 100 μl. The concentrated viral vectors were subjected to albumin removal using an albumin serum removal kit (Genomic Solutions, Ann Arbor, MI, USA) following the protocol as described by the manufacturer. The resulting viral vector solution was centrifuged at 24 000 *g* for 2 h at 4°C. The viral pellet was dissolved in 15 μl of an SDS-containing sample buffer, and 5 μl of the resulting lysed virus was loaded into the same gel and blotted on to the same membrane as above. The blot was then blocked as described above and subsequently incubated with a 1/10 000 dilution of goat polyclonal antisera against disrupted Rauscher leukemia virus (ID 71S000126, NCI/BCB Repository), which crossreacts with the protein components of Moloney murine leukemia virus. Blots were then treated with a 1/100 000 dilution of sheep anti-goat polyclonal antibodies conjugated to peroxidase and subjected to ECL for visualization.

### *Reverse transcriptase assays*

Tel-Ampho vector (6 ml) was pelleted by centrifugation at 24 000 *g* for 2 h at 4°C. The viral pellet was resuspended in 130 μl of PBS (pH 7.4). Concentrated viral vector (80 μl) was then treated with 2.5 mg/ml NHS-PC-LC-Biotin/10% DMF for 150 min on ice, in the dark. In parallel, 40 μl of the concentrated viral vector was with 10% DMF alone for 150 min on ice, in the dark. NHS-PC-LC-Biotin-treated viral vector (40 μl) was exposed to 365-nm light for 6 min at a distance of 0.5 cm as described above. The other 40 μl of biotinylated vector was allowed to stand in the dark at room temperature for 6 min. All viral vectors were then divided into 20 μl aliquots, each mixed with 20 μl of a lysis buffer (50 mM Tris-Cl, 80 mM potassium chloride, 2.5 mM DTT, 0.75 mM EDTA, and 0.5% Triton X-100, pH 7.8). Lysed viral vectors were then combined with 50 μl of a reverse transcriptase reaction buffer containing deoxyribonucleotides and template RNA (provided by the Non-Radioactive Reverse-Transcriptase Assay Kit, Boehringer Mannheim, Indianapolis, IN, USA). Manganese chloride was added to a final concentration of 12 mM. α-$^{32}$P-dTTP, 7 μl, was also added to allow for detection of RT reaction products. Lysed viral vectors mixed with the reaction buffer were incubated at 42°C and incubated overnight. Each reaction mixture (10 μl) was spotted on DE81 filter paper (Whatman, Clifton, NJ, USA), dried, and washed three times with 2 × SSC. After washing, the spotted filter papers were dried after soaking them in 95% ethanol and radioactivity was assessed by liquid scintillation counting.

### *Viral interference assays*

Inactivated Tel-Ampho particles were prepared by treating a stock of Tel-Ampho with a psoralen derivative, AMT, followed by irradiation with long-wavelength UV light. These psoralen-inactivated viral vectors were tested for their ability to interfere with the infection of viral target cells (D-17) by unaltered Tel-Ampho. In parallel, Tel-SNV (TelCeB6-derived viral cores bearing the envelope glycoprotein of spleen necrosis virus) and NHS-PC-LC-Biotin-treated Tel-Ampho (using 2.5 mg/ml NHS-PC-LC-Biotin) were also tested for their ability to interfere with the ability of unaltered Tel-Ampho vectors to infect target D-17 cells. Stocks of inactivated Tel-Ampho and Tel-SNV particles were constructed as follows. The viral vector stock (1.6 ml) was combined with 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) at a final concentration of 50 μg/ml. After 30 min of incubation at room temperature in the dark, viral vector-AMT mixtures were exposed to 365 nm for 15 min at a distance of 2 cm from the light source. Following irradiation, AMT-inactivated viral vector was centrifuged at 8000 *g* for 10 min at 4°C to remove gross cellular debris. Virus-containing supernatants were then concentrated to a volume of 420 μl by ultrafiltration using YM-100 (100 kDa molecular mass cut-off) filtration devices. Concentrated viral vector was separated into two 200-μl aliquots and treated with either 2.5 mg/ml NHS-PC-LC-Biotin/10% DMF or 10% DMF alone, on ice in the dark for 150 min, followed by addition of 200 μl of 100 mM glycine/PBS (pH 7.4). Inactivated, concentrated and NHS-PC-LC-Biotin-treated (or non-biotinylated) viral vector (20 μl) was then combined with 2.5 μl of unaltered Tel-Ampho from the same viral vectors stock as the one used to prepare inactivated viral particles. These mixtures were placed over monolayers of either $1 \times 10^4$ or $5 \times 10^3$ D-17 cells in a total volume of 100 μl of DMEM/6% FBS containing 5 μg/ml polybrene. After 4 h of incubation at 37°C, the culture medium over the D-17 cells was replaced with fresh DMEM/6% FBS. After exposure of cells to viral vectors (48 h), cells were fixed in 0.5% paraformaldehyde and stained with X-gal to reveal infected (*lac*Z-expressing) cells as described above.

## Acknowledgements

We thank Kenneth J Rothschild and Jerzy Olejnik for useful discussions and providing photocleavable biotin samples, John C Guatelli and Jonathan Loeb for critical reading of the manuscript, Yasuhiro Takeuchi for the cell line TelCeB6, F-L Cosset for the plasmid pA, R Dornburg for pRD134, and Ruo Jie Wang and Muhammad-Omar Raiss for technical assistance. MWP is supported by a postdoctoral fellowship from the US Department of Army Prostate Cancer Research Program, PC990029.

## References

1 Miller AD. Development and applications of retroviral vectors. In: Coffin JM, Hughes SE, Varmus HE (eds). *Retroviruses*. Cold Spring Harbor Laboratory Press: Plainview, NY, 1998, pp 438–473.
2 Benedict CA *et al*. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. *Hum Gene Ther* 1999; **10**: 545–557.
3 Cosset F *et al*. Retroviral retargeting by envelopes expressing an N-terminal binding domain. *J Virol* 1995; **69**: 6314–6322.
4 Somia NV, Zoppe, M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to *in vivo* gene delivery. *Proc Natl Acad Sci USA* 1995; **92**: 7570–7574.
5 Chu TT, Dornburg R. Toward highly efficient cell type-specific gene transfer with retroviral vectors displaying single-chain antibodies. *J Virol* 1997; **71**: 720–725.
6 Cosset F *et al*. High titer retroviral packaging systems which produce human complement-resistant retroviral vectors. *J Virol* 1995; **69**: 7430–7436.
7 Olejnik J, Sonar S, Krzymanska-Olejnik E, Rothschild KJ. Photocleavable biotin derivatives. A versatile approach for the isolation of biomolecules. *Proc Natl Acad Sci USA* 1995; **92**: 7590–7594.
8 Wong SS. *Chemistry of Protein Conjugation and Cross-linking*. CRC Press: Boca Raton, FL, 1991.
9 Hermanson GT. *Bioconjugate Techniques*. Academic Press, New York, 1995.
10 Riggs JL, McAllister RM, Lennette EH. Immunofluorescent studies of RD-114 virus replication in cell culture. *J Gen Virol* 1974; **25**: 21–29.
11 McKeating JA, McKnight A, Moore JP. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. *J Virol* 1991; **69**: 852–860.
12 Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. *Anal Biochem* 1987; **166**: 368–379.
13 Petropoulos C. Retroviral taxonomy, protein structures, sequences, and genetic maps. In: Coffin JM, Hughes SE, Varmus HE (eds). *Retroviruses*. Cold Spring Harbor Laboratory Press: Plainview, NY, 1998, pp 757–805.
14 Swanstrom R *et al*. Interaction of psoralen derivatives with the RNA genome of rous sarcoma virus. *Virology* 1981; **113**: 613–622.
15 Hanson CV. Photochemical inactivation of viruses with psoralens: an overview. *Blood Cells* 1992; **18**: 7–25.
16 Redfield DC, Richman DD, Oxman MN, Kronenberg LH. Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells. *Infect Immunol* 1981; **32**: 1216–1226.
17 Schuberth H-J *et al*. Biotinylation of cell surface MHC molecules: a complimentary tool for the study of MHC class II polymorphism in cattle. *J Immunol Meth* 1996; **189**: 89–98.

Classification: BIOLOGICAL SCIENCES, Applied Biological Sciences

# Photoactivatable Adenoviral Vectors

**Mark W. Pandori*[¶], David A. Hobson*[¶], Jerzy Olejnik[†], Edyta Krzymanska-Olejnik[†], Kenneth J. Rothschild[‡], Abraham A. Palmer[§], Tamara J. Phillips[§], and Takeshi Sano***

*Center for Molecular Imaging Diagnosis and Therapy and Basic Science Laboratory, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115; [†]AmberGen, Inc., 1106 Commonwealth Avenue, Boston, MA 02215; [‡]Department of Physics and Molecular Biophysics Laboratory, Boston University, Boston, MA 02215; [§]Department of Behavioral Neuroscience, Oregon Health Sciences University, Portland, OR 97201

[¶] These authors contributed equally to this work.

Corresponding author: Takeshi Sano, Beth Israel Deaconess Medical Center, HIM 118, 77 Avenue Louis Pasteur, Boston, MA 02115. Telephone 617-667-0142; FAX 617-975-5560; e-mail tsano@caregroup.harvard.edu

Text, 18 pages; figures, 7 pages; abstract, 1,026 characters; text, 31,162 characters

Abbreviations: DMF, dimethylformamide; NHS, *N*-hydroxysuccinimide or *N*-hydroxysuccinimidyl; PCB, photocleavable biotin (NHS-LC-PC-Biotin); WSPCB, a water-soluble version of PCB; X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside.

We have explored a novel strategy for controlling the infectivity of adenoviral vectors. This strategy involves a method whereby the infectivity of an adenoviral vector is neutralized by treatment of viral particles with a water-soluble, photocleavable biotinylation reagent. These modified viral vectors possess little to no infectivity for target cells. Exposure of these modified viral vectors to 365-nm light induces a reversal of the neutralizing, chemical modification, resulting in restoration of infectivity to the viral vector. This strategy worked efficiently for *in vitro* light-directed infection of target cells. This use of photoactivatable adenoviral vectors was also successfully employed for the transduction of a specific tumor site within a live mouse. This infectivity trigger possesses great potential, both as a research tool and as a novel tactic for the targeting of gene-transfer agents, since it would become possible to direct both the time and location of a viral infection in a versatile manner.

Adenoviral vectors have become one of the most useful gene transfer agents (1-5). They are structurally stable and can be produced to high infectious titers (up to ~ $10^{12}$ infectious units/ml). Their genome can be easily manipulated to deliver large transgenes. Adenoviral vectors can infect a wide range of cells, including non-dividing cells. These characteristics make adenoviral vectors a particularly attractive tool for a wide variety of gene transfer applications. However, the broad target cell range of adenoviral vectors has two consequences that limit their utility for *in vivo* gene transfer applications, such as gene therapy. First, their broad tropism can result in the delivery of the transgene in a non-specific manner. Second, large doses of undirected adenoviral vectors would be required to ensure an adequate amount of gene transfer to the target site. Thus, the ability to control the delivery of adenoviral vectors in a controlled or directed manner is of paramount importance in the development of adenovirus-based *in vivo* gene transfer protocols.

We have explored a novel strategy for controlling the infectivity of adenoviral vectors. This strategy employs a chemical agent that modifies adenoviral vectors in a reversible fashion such that their infectivity is eliminated but can be restored upon application of an external stimulus. This strategy allows for both the location and timing of adenovirus-mediated gene transduction to be externally controllable.

## Materials and Methods

**Adenoviral Vectors and Target Cells.** The adenoviral vector used in this study, Ad5.CMV-LacZ (Qbiogene, Montreal, Canada), is derived from adenovirus serotype 5 with the deletion of the viral E1A, E1B, and E3 genes. The adenoviral vector carries the bacterial *lac*Z gene (β-

galactosidase) under the control of the human cytomegalovirus immediate-early promoter. This viral vector was produced by using 293A cells (Qbiogene), a sub-line of 293 cells (human embryonal kidney cells transformed by sheared adenovirus serotype 5 genome), and purified by two rounds of CsCl gradient centrifugation, followed by removal of CsCl by dialysis against 10 mM Tris-Cl pH 8.0, 2 mM $MgCl_2$, 4% sucrose (6, 7). The original preparation was diluted to 1 x $10^{10}$ viral particles/ml (1 x $10^9$ infectious units/ml) and stored at – 70 °C until used. The dog osteosarcoma cell line D-17 (American Type Culture Collection) was maintained in DMEM supplemented with 6% FBS (BioWhittaker).

**Infectivity Assays.** The infectivity of adenoviral vectors was determined by using D-17 cells as targets. An adenoviral vector stock was placed over monolayers of 5 x $10^4$ D-17 cells in a 24-well plate and incubated at 37 °C for 24 hr. Cells were washed once with culture medium and incubated at 37 °C for 24 hr to permit the expression of the *lac*Z gene. Then, cells were fixed with 0.5% glutaraldehyde and stained for β-galactosidase activity using 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) as the substrate. Infected, *lac*Z-expressing cells (stained blue) were counted under a light microscope.

**Synthesis of Photocleavable Biotinylation Reagents.** A photocleavable biotin (PCB; NHS-PC-LC-biotin) (Fig. 1A) was synthesized as previously described (8). A water-soluble derivative of PCB, WSPCB (Fig. 1A), was synthesized by using the following procedure (Fig. 1B). All chemicals were obtained from Aldrich, except benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) which was from Novabiochem. 5-Aminomethyl-2-nitroacetophenone hydrochloride (1.73 g, 7.5 mmol) (compound 1) was dissolved in 60 ml of

dimethylformamide (DMF). To this solution, *N,N'*-diisopropylethylamine (DIPEA; 1.2 ml), 2,6-dimethylaminopyridine (DMAP; 0.46 g, 3.75 mmol), and succinic anhydride (0.75 g, 7.5 mmol) were added. The reaction mixture was stirred at room temperature overnight, added to 120 ml of 0.1 M HCl, and extracted three times, each with 50 ml of chloroform. Organic extracts were combined, dried, and evaporated. Crude products were recrystallized from acetonitrile to give compound 2 (1.2 g, 49% yield). To a stirred solution of 2,2'-(ethylenedioxy)-bis-(ethylamine) (2 g; 13.5 mmol) (compound 3) in 100 ml of acetonitrile, a solution of 9-fluorenylmethoxycarbonyl *N*-hydroxysuccinimide (Fmoc-NHS; 4.95 g, 14.8 mmol) in 50 ml of acetonitrile was added over the course of 30 min. The reaction mixture was stirred for an additional 1 hr, concentrated under reduced pressure, and purified on a silica gel using 0 - 6% methanol step-gradient in chloroform/0.8% triethylamine. Fractions containing a mono-Fmoc derivative were pooled and evaporated to give 2.50 g of compound 4 (52% yield). To a stirred solution of compound 4 (2.5 g, 7 mmol) in 50 ml of methanol, a solution of biotin-NHS (2.63 g, 7.7 mmol) in 60 ml of 95% methanol was added over the course of 15 min. After 1 hr at room temperature, thin layer chromatography (chloroform/methanol/acetic acid, 9:1:1 v/v/v) showed complete conversion into compound 5. The mixture was then concentrated under reduced pressure and purified on a silica gel using a 0 - 6% methanol step-gradient in chloroform to give 2.2 g of compound 5 (54% yield). Compound 5 (2.2 g, 3.8 mmol) was added to 6 ml of 20% piperidine in DMF. The resulting solution was stirred at room temperature for 10 min, concentrated to about 2 ml under reduced pressure, and added to 20 ml of cold ether. After incubation at – 70 °C for 30 min, the precipitate was collected by centrifugation. The precipitate (compound 6) was dissolved in 2 ml of methanol, re-precipitated as above, and dried (yield 1.1 g, 82%). Compound 2 (5-succinylamidomethyl-2-nitroacetophenone) (0.59 g, 1.94 mmol) was dissolved in 3 ml of DMF.

To this solution, a solution of PyBOP (0.99 g, 1.94 mmol) in 3 ml DMF was added, followed by the addition of *N,N*-diisopropylethylamine (0.68 ml, 3.9 mmol). The resulting solution was stirred at room temperature for 15 min, and then a solution of compound 6 (0.68 g, 1.94 mmol) in 3 ml DMF was added. Stirring continued overnight, and solvents were evaporated under reduced pressure. The residue was purified on a silica gel column using a 0 - 20% step-gradient of methanol in chloroform to give 0.75 g of compound 7 (67% yield). Reduction with sodium borohydride and conversion to the target NHS carbonate were carried out as described previously (8).

**Treatment of Adenoviral Vectors with PCB and WSPCB.** A stock solution of PCB (25 mg/ml in DMF) was diluted in PBS pH 7.4, and the diluted PCB (25 µl) was added to 2.5 x $10^6$ adenoviral vector particles (2.5 x $10^5$ infectious units) in PBS (25 µl). The biotinylation reactions were performed on ice in the dark for 2 hr and terminated by the addition of 100 µl DMEM/10% FBS. Treatment of adenoviral vectors with WSPCB was performed in the same manner, except that the WSPCB stock solution used had a concentration of 100 mg/ml in DMF.

**Photo-irradiation of WSPCB-treated Adenoviral Vectors.** Adenoviral vectors were treated with various concentrations of WSPCB as above. WSPCB-treated viral vectors were divided into two groups of borosilicate glass vials. One group of borosilicate glass vials was kept in the dark, while the other group was irradiated for 3 min with 365-nm light using a UV lamp (model B-100 SP; UV Products, Inc.) equipped with a 160-W mercury vapor bulb, which emits long-wavelength UV light in the 355 - 375 nm range peaking at 365 nm. Actual light intensities in this and other experiments were determined by using a UV light meter (model 06-662-65; UV

Products, Inc.). The infectivity of the non-irradiated and irradiated adenoviral vectors was analyzed by using D-17 cells. The time course of the infectivity activation of WSPCB-treated adenoviral vectors upon photo-irradiation was investigated in a similar manner, except that the exposure time to 365-nm light was varied.

**Western Blotting Analysis.** Adenoviral vectors, which had been treated with WSPCB as above, were placed in borosilicate glass vials ($1.2 \times 10^9$ viral particles per vial). One vial was kept in the dark, while the other vial was exposed for 4 min to 365-nm light as above. Each of these viral samples was centrifuged at 25,000 x *g* for 2 hr at 4°C to precipitate adenoviral vectors. Viral precipitates were suspended in 10 μl of an SDS sample solution containing 20 mM 2-mercaptoethanol and electrophoresed on 4 - 20% polyacrylamide gradient gels (9). Proteins were transferred from the gel to polyvinylidene difluoride membrane (Millipore) by using a semi-dry electroblotter. The membrane was blocked with SuperBlock (Pierce) and then incubated for 30 min with a streptavidin-alkaline phosphatase conjugate (Pierce), diluted 5000-fold in SuperBlock. Bound streptavidin-alkaline phosphatase conjugates were visualized by alkaline phosphatase activity using nitroblue tetrazolium chloride/5-bromo-4-chloro-3'-indolylphosphate *p*-toluidine salt (Pierce) as the substrates.

**Virus Adsorption Assay.** Adenoviral vectors ($1.25 \times 10^9$ viral particles per reaction) were treated with 1 mg/ml WSPCB as above. The resulting viral vectors were either irradiated with 365-nm light (16 $mW/cm^2$) for 3 min or kept in the dark. Each of these samples was added to a monolayer of D-17 cells cultured on a culture dish, and the mixtures were incubated at 37 °C for 3 hr. The supernatant (culture medium fraction) containing unbound adenoviral vectors was

collected and irradiated with 365-nm light for 3 min as above (this irradiation step was omitted for adenoviral vectors that had been irradiated with 365-nm light). The infectivity of the resulting viral vectors was analyzed by using fresh D-17 cells to estimate the amount of adenoviral vectors that remained unbound. Adenoviral vectors without WSPCB treatment were used as controls. Non-specific binding of adenoviral vectors was estimated by using empty culture dishes.

***In Vivo* Activation of WSPCB-treated Adenoviral Vectors.** Mouse subcutaneous tumor models were prepared by using D-17 cells and 9-week-old athymic nude mice (Hsd: Athymic Nude-*nu/nu*; Harlan). D-17 cells ($2 \times 10^7$ in 200 µl PBS per injection) were injected percutaneously on each side of the back of the mice just above the upper legs. After 24 hr, small tumor nodules (3 - 5 mm) formed in these mice on both sides (at both injection sites). Adenoviral vectors were treated with 0.5 mg/ml WSPCB as above. *In vitro* analysis using D-17 cells showed that the infectivity of the resulting WSPCB-treated viral vectors was inhibited to near completion and that the infectivity can be reactivated efficiently upon irradiation of 365-nm light.

Each tumor site of the mice was injected with 250 µl of the WSPCB-treated adenoviral vectors ($2.3 \times 10^9$ infectious units prior to the treatment) prepared above. After briefly massaging the injection sites, each mouse was anesthetized and covered with aluminum foil with a hole to expose only the right-hand tumor sites. Exposed tumor sites were irradiated at a distance of 12 cm with a 365-nm UV lamp (model B-100SP) for two 2-min periods, separated by a 30-sec intermission. Mice were maintained for 48 hr and then sacrificed, followed by the collection of tumor sites with adjoining tissue. Tissue was sectioned (50-µm sections) in a CM 1850 Cryostat (Leica) at - 14 °C. Tissue sections were stained for the expression of the *lac*Z gene using X-gal as the substrate, and the stained tissue sections were viewed under a light microscope.

## Results and Discussion

We have created a novel strategy for controlling the infectivity of adenoviral vectors. This strategy involves a method whereby the infectivity of an adenoviral vector is first neutralized by a reversible chemical modification. Reversal of this chemical modification allows for the restoration of infectivity to the adenoviral vector. This strategy had recently been successfully implemented on retroviral vectors derived from amphotropic Moloney murine leukemia virus by using PCB as the modification reagent (10). PCB (Fig. 1A) (8) contains a biotin moiety linked though a spacer arm to a 1-(2-nitrophenyl)ethyl group, which is derivatized with an NHS ester. The NHS ester reacts selectively with primary aliphatic amino groups, such as N-termini and lysine residues on proteins, which are abundant in viral vectors, to form a carbamate bond. When PCB-biomolecule conjugates are exposed to 300 - 365 nm light, the PCB moiety undergoes an intramolecular photochemical reaction, which involves the cleavage of the carbamate bond. This results in the regeneration of the primary amino group on the biomiolecule and releases the PCB moiety, in which the 1-(2-nitrophenyl)ethyl group is converted to a 2-nitrosoacetophenone derivative (8). PCB is highly hydrophobic and exhibits low solubility in aqueous media. To reduce hydrophobicity and increase solubility in aqueous media, a water-soluble version of PCB, WSPCB, was synthesized. WSPCB is structurally similar to PCB, but it has a mixed polarity spacer arm between the biotin and 1-(2-nitrophenyl)ethyl moieties (Fig. 1A). The synthesis of WSPCB (Fig. 1B) involved the production of a mono-biotinylated derivative of 2,2'-(ethylenedioxy)-bis(ethylamine), which was then conjugated to 5-succinylamidomethyl-2-nitroacetophenone. The resulting intermediate was converted to a reactive NHS derivative.

In order to determine if the infectivity of adenoviral vectors could be eliminated by treatment with either PCB or WSPCB, adenoviral vectors were exposed to various concentrations of PCB or WSPCB. The adenoviral vectors used contain a transducable *lac*Z gene, which provides a simple means of detecting transduced cells. Treatment with WSPCB at 1 mg/ml or greater virtually eliminated the infectivity of these vectors (Fig. 2A). In contrast, treatments with PCB were considerably less effective at inhibiting the infectivity of these vectors than with WSPCB at the same concentrations (Fig. 2B). Retroviral vectors, when treated with PCB, showed a behavior contrary to this finding (10). PCB was highly effective at abrogating retroviral infectivity at concentrations of 1 - 2 mg/ml. This differential sensitivity of retroviral and adenoviral vectors to these two biotinylation reagents may be derived from the vast differences in the structures and properties of the outer surfaces of these viruses. Having observed the sensitivity of the adenoviral vectors to biotinylation by WSPCB, we determined the concentration range in which WSPCB could function to modulate viral infectivity (Fig. 2C). Treatment with as low as 0.1 mg/ml WSPCB reduced infectivity by nearly 50%. Treatment with WSPCB at concentrations greater than 0.4 mg/ml virtually eliminated the infectivity of these vectors.

We tested whether the infectivity of the biotinylated adenoviral vector could be recovered via photocleavage of the WSPCB molecule from the viral particles. Adenoviral vectors were treated with various concentrations of WSPCB, and then either kept in the dark or exposed to 365-nm light. These samples were analyzed for their infectivity by using D-17 cells (Fig. 3A). WSPCB-treated, nonirradiated adenoviral vectors showed virtually no infectivity. In contrast, when WSPCB-treated viral vectors were exposed to 365-nm light, their infectivity was restored. At an energy output of 16 $mW/cm^2$, restoration of infectivity occurred within 1 min of exposure

to 365-nm light, with maximum recovery occurring after 3 min of irradiation (Fig. 3B). Irradiation with 365-nm light beyond 3 min did not enhance the recovery of infectivity. Instead, the infectivity of irradiated vectors decreased slightly with prolonged exposure, possibly because of damage to adenoviral vectors caused by shorter-wavelength radiation emitted from the UV light source.

We next attempted to determine whether the reactivation of adenoviral infectivity could be done, *in situ*, in the presence of target cells. Adenoviral vectors, treated with 1 mg/ml WSPCB, were added to D-17 cells growing in borosilicate glass vials. These vials were either kept in the dark or irradiated with 365-nm light. Infection assays of cells, which had been exposed to WSPCB-treated adenovirus vectors and kept in the dark, showed negligible amounts of infection, while great amounts of infection were observed in cells exposed to WSPCB-treated adenoviral vectors and irradiated with 365-nm light (Fig. 4). Irradiation with 365-nm light showed no appreciable effects on cell viability. These experiments were performed by using WSPCB-treated adenoviral vectors, which had been washed of free, unreacted WSPCB by repeated rounds of ultrafiltration. This ensured that the photoactivatable infectivity of adenoviral vectors, shown above, would not be based on the presence of non-virion-associated WSPCB.

The results described above imply that WSPCB is covalently attached to viral particles upon treatment and that the association of WSPCB with virions is responsible for the photoactivatable infectivity of treated vectors. To determine whether WSPCB is associated with virions, and, if so, whether irradiation with 365-nm light causes cleavage of virion-associated WSPCB, Western blotting analysis was performed. Adenoviral vectors were treated with 1 mg/ml WSPCB, and either irradiated with 365-nm light or kept in the dark. The resulting viral proteins were separated by SDS-PAGE, transferred to a membrane, and probed for conjugated

WSPCB with a streptavidin-alkaline phosphatase conjugate (Fig. 5). Biotinylation was observed on 84-kDa and 134-kDa proteins in samples derived from WSPCB-treated, nonirradiated adenoviral vectors (lane 1). The amount of WSPCB, bound to these proteins, was markedly reduced when WSPCB-treated viral vectors had been exposed to 365-nm light (lane 2). These results demonstrate that irradiation of WSPCB-treated adenoviral vectors with 365-nm light cleaves and subsequently liberates WSPCB from virions. These data strongly suggest that the conjugation of WSPCB to adenoviral vectors and cleavage of virion-associated WSPCB is the infectivity-controlling factor.

As shown above, WSPCB is vastly more effective than PCB in inhibiting the infectivity of adenoviral vectors. The primary difference in properties between the two biotinylation reagents, i.e., hydrophilicity, suggests that the mechanism of infectivity inhibition by these reagents is based on the modulation of the function of viral proteins on the outer, solvent-exposed viral surface. Hence we hypothesized that the ability of adenoviral vectors to either bind or enter target cells is disrupted upon treatment with WSPCB. To test this hypothesis, we devised an assay that quantifies the ability of viral particles to be adsorbed by target cells. Adenoviral vectors were treated with 1 mg/ml WSPCB and incubated over a monolayer of D-17 cells in a culture dish or in an empty culture dish for 3 hr. Then, culture supernatants containing unbound viral vectors were collected, exposed to 365-nm light, and added to fresh D-17 cells for analysis of infectious titers. Comparison of the infectious titers of adenoviral vectors incubated with D-17 cells and those incubated in an empty culture dish indicates a percentage of viral vectors that were associated with the D-17 cells (Fig. 6). WSPCB-treated adenoviral vectors exhibited minimal levels of cell association. Adenoviral vectors, which had been treated with WSPCB and irradiated with 365-nm light prior to incubation with D-17 cells, showed levels of cell

association equivalent to those of untreated adenoviral vectors. This data suggests that the conjugation of WSPCB to adenoviral vectors inhibits their infectivity by interfering with their ability to bind to target cells, and that irradiation with 365-nm light restores the binding ability of these vectors for target cells by releasing virion-associated WSPCB.

Following the successful development and characterization of photoactivatable adenoviral vectors in an *in vitro* setting, we tested the potential of these adenoviral vectors to be used for *in vivo* gene transfer applications using tumors growing in nude mice as viral targets. Athymic nude mice were each injected percutaneously with D-17 on each side of the back of the mice just above the upper legs. After the formation of small tumor nodules on both sides of the mice, tumor sites were injected with adenoviral vectors that had been treated with 0.5 mg/ml WSPCB (these treated viral vectors showed photoactivatable infectivity *in vitro* with cultured D-17 cells; data not shown). The mice were covered in an aluminum foil cloak, which was designed and cut in a way such that only one tumor site was exposed. Exposed tumor sites were irradiated externally with 365-nm light for 4 min through the skin over the tumor nodule. The mice were sacrificed at 48 hr after irradiation, and the tumor nodules, along with adjoining tissue, were collected, sectioned, and stained for the expression of the *lac*Z gene. Sections of tumor sites that were not exposed to 365-nm light show very few, if any, infected cells (Fig 7). However, sections of injected tumor sites that were irradiated with 365-nm light through the skin show a large number of infected cells. This indicates that the infectivity of WSPCB-treated adenoviral vectors can be reactivated *in vivo* by external photo-irradiation. This also demonstrates that the inactivation of viral infectivity with WSPCB is a modification that is not reversed under physiological, unirradiated conditions. Apparently, the skin did not function as a complete barrier to the reactivating light. The skin that was positioned over the irradiated tumor sites was

also not noticeably affected by the irradiation. These data demonstrate the potential that WSPCB-treated adenoviral vectors can be used to direct adenovirus-based gene transduction in a site-specific manner within whole animals.

**Conclusions.** We have demonstrated a method of making adenoviral vectors selectively activatable by an external stimulus. Conjugation of a PCB derivative, WSPCB, virtually eliminates the infectivity of adenoviral vectors in a reversible manner. Exposure of WSPCB-treated viral vectors to 365-nm light restores infectivity to levels approaching those prior to biotinylation. Inhibition and restoration of the infectivity of adenoviral vectors has successfully been demonstrated both *in vitro* and *in vivo.* This infectivity trigger holds considerable potential for the targeting of adenoviral vectors, since the site-specific delivery of transgenes to target sites could be mediated by the application of 365-nm light focused on the target sites. The viral surface biotin moiety should also be useful for further modification of the viral surface. For example, biotinylated materials can be attached to viral surface biotin moieties by using streptavidin as a molecular bridge with little effect on the cleavage efficiency of virion-associated PCB by photo-irradiation (M.W.P., D.A.H. & T.S., unpublished data).

MWP was supported by a postdoctoral fellowship, PC990029, from the U.S. Department of Army Prostate Cancer Research Program. This work was supported by Grant CA46109 from the National Institutes of Health.

1. Kay, M. A., Glorioso, J. C. & Naldini, L. (2001) *Nature Med.* **7**, 33-40.
2. Hackett, N. R. & Crystal, R. G. (2000) in *Gene Therapy: Therapeutic Mechanisms and Strategies*, eds. Templeton, N. S. & Lasic, D. D. (Marcel Dekker, New York), pp. 17-40.
3. Hitt, M. M., Parks, R. J. & Graham, F. L. (1999) in *The Development of Human Gene Therapy*, ed. Friedmann, T. (Cold Spring Harbor Laboratory Press, Plainview, NY), pp. 61-86.
4. Wivel, N. A., Gao, G.-P. & Wilson, J. M. (1999) in *The Development of Human Gene Therapy*, ed. Friedmann, T. (Cold Spring Harbor Laboratory Press, Plainview, NY), pp. 87-110.
5. Benihaud, K., Yeh, P. & Perricaudet, M. (1999) *Curr. Opin. Biotechnol.* **10**, 440-447.
6. Mittereder, N., March, K. L. & Trapnell, B. C. (1996) *J. Virol.* **70**, 7498-7509.
7. Nyberg-Hoffman, C. & Aguilar-Cordova, E. (1999) *Nature Med.* **5**, 955-957.
8. Olejnik, J., Sonar, S., Krzymanska-Olejnik, E. & Rothschild, K. J. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 7590-7594.
9. Schägger, H. & von Jagow, G. (1987) *Anal. Biochem.* **166**, 368-379.
10. Pandori, M. W. & Sano, T. (2000) *Gene Ther.* **7**, 1999-2006.

**Fig. 1.** A. Structures of photocleavable biotin (NHS-LC-PC-Biotin; PCB) and its water-soluble derivative, WSPCB. B. Synthesis scheme of WSPCB.

**Fig. 2.** Effect of treatment with WSPCB (A, C) or PCB (B) on the infectivity of adenoviral vectors. A stock solution of WSPCB or PCB, both in DMF, was diluted in PBS pH 7.4. The diluted WSPCB or PCB (25 μl) was allowed to react with adenoviral vectors ($2.5 \times 10^6$ viral particles in 25 μl PBS) for 2 hr. The infectivity of the resulting viral vectors was assayed by using D-17 cells. DMF at concentrations used during treatment with WSPCB or PCB (up to 8%) showed no effect on infectivity and cell viability.

**Fig. 3.** A. Photo-activation of WSPCB-treated adenoviral vectors. Adenoviral vectors were treated with various concentrations of WSPCB, placed into borosilicate glass vials, and either kept in the dark (solid bars) or irradiated with 365-nm light (16 $mW/cm^2$) for 3 min (hatched bars). The resulting viral vectors were added to monolayers of D-17 cells ($5 \times 10^4$ per well) to analyze their infectivity. B. Time course of the restoration of the infectivity of WSPCB-treated adenoviral vectors. Adenoviral vectors were treated with 1 mg/ml WSPCB and irradiated with 365-nm light (16 $mW/cm^2$) for the durations indicated. The infectivity of the irradiated viral vectors was analyzed by using D-17 cells.

**Fig. 4.** *In situ* photo-activation of WSPCB-treated adenoviral vectors. Adenoviral vectors were treated with 1 mg/ml of WSPCB. The resulting viral vectors were purified away from unreacted WSPCB by ultrafiltration, and small aliquots (1 μl or 25 μl) of the purified viral vectors were

placed within each of four 3-ml borosilicate glass vials containing monolayers of D-17 cells (5 x $10^4$ per vial) covered with 500 μl of DMEM/6% FBS. Two of the vials were placed in the dark (solid bars), while the other two vials were exposed to 365-nm light (16 mW/cm$^2$) for 4 min (hatched bars). At 48 hr after irradiation, cells were stained for the expression of the *lac*Z gene. Shown are the results from two independent experiments with different viral innocula.

**Fig. 5.** Western blotting analysis of WSPCB-treated adenoviral vectors. Adenoviral vectors were treated with 1 mg/ml WSPCB and either kept in the dark (lane 1) or irradiated with 365-nm light (16 mW/cm$^2$) for 4 min (lane 2). The resulting viral vectors were subjected to SDS-PAGE, and proteins were transferred to polyvinylidene difluoride membrane. Biotinylated viral proteins were detected by using a streptavidin-alkaline phosphatase conjugate (Pierce).

**Fig. 6.** Adsorption assays of WSPCB-treated adenoviral vectors. Adenoviral vectors were treated with 1 mg/ml WSPCB and incubated for 3 hr over monolayers of D-17 cells grown in a 35-mm culture dish. The same viral vector sample was also incubated in an empty 35-mm culture dish to estimate non-specific binding of virions to culture dishes. The supernatants (culture medium fractions) containing unbound virions were collected and exposed to 365-nm light (16 mW/cm$^2$) for 3 min. Adenoviral vectors, which had been treated with 1 mg/ml WSPCB and exposed to 365-nm light prior to the application to D-17 cells or an empty tissue culture dish, were also used in the same manner. Adenoviral vectors without WSPCB treatment were used as controls. All supernatants were subjected to infectivity analysis using fresh D-17 cells. The percentage of cell-associated virions for each sample is calculated as: [(Infectivity remaining in the supernatant

after incubation in an empty dish) – (infectivity remaining in the supernatant after incubation with D-17 cells)] / (infectivity remaining in the supernatant after incubation in an empty dish).

**Fig. 7.** *In vivo* photo-activation of WSPCB-treated adenoviral vectors. Mouse subcutaneous tumor models were prepared by using D-17 cells and athymic nude mice as described in Materials and Methods. After small tumor nodules (3 - 5 mm) formed in these mice, each tumor site was injected with WSPCB-treated adenoviral vector (250 μl). Mice were anesthetized and covered with aluminum foil with a hole to expose only the right-hand tumor sites. Exposed tumor sites were irradiated with 365-nm light for two 2-min periods, separated by a 30-sec intermission. At 48 hr after irradiation, mice were sacrificed, followed by the collection of tumor sites with adjoining tissue. Tissue was sectioned (50-μm sections), and the resulting tissue sections were stained for the expression of the *lac*Z gene using X-gal as the substrate. The stained tissue sections were viewed under a light microscope. a - c, no irradiation (control); d - f, irradiated with 365-nm light.


A
NHS ester
Biotin
Spacer
1-(2-Nitrophenyl)ethyl
PCB (NHS-PC-LC-biotin)
WSPCB (water-soluble PCB)
B
DMAP
Fmoc-NHS
Biotin-NHS
PyBOP
DIPEA
1
2
3
4
5
6
7

Fig. 1


A
100
80
60
40
20
0
% Infectivity
0
1
1.5
2
Concentration of WS-PC-Biotin (mg/ml)
B
100
80
60
40
20
0
% Infectivity
0
1
1.5
2
Concentration of NHS-PC-LC-Biotin (mg/ml)
C
100
80
60
40
20
0
% Infectivity
0
0.1
0.2
0.3
0.4
0.5
Concentration of WS-PC-Biotin (mg/ml)

Fig. 2


A
100
80
60
40
20
0
% Infectivity
0
1
1.5
2
Concentration of WS-PC-Biotin (mg/ml)
B
100
80
60
40
20
0
% Infectivity
0
2
4
6
8
10
Time of Exposure to 365-nm Light (min)

Fig. 3


Number of infected cells
per microliter of applied viral vectors
1000
800
600
400
200
0
1 µl
25 µl
Volume of applied viral vectors

Fig. 4




Fig. 5


40
30
20
10
0
% Cell associated
Untreated
WSPCB-treated
WSPCB-treated and irradiated

Fig. 6

7.



© 2001 Nature Publishing Group http://medicine.nature.com


# Research News

## Gene therapy sees the light

A light-activated vector offers a new strategy for a targeted and inducible gene delivery. Although gene therapy has advanced from proof of principle to early stage clinical trials, it has not proven to be the medical panacea that many had hoped, due to problems associated with efficiency and precision of gene delivery. Viral vectors are the current delivery method of choice, but these friendly Trojan horses can infect a wide range of tissues *in vivo*. In the December issue of *Gene Therapy*, Pandori and Sano report the construction of a photo-activated vector whose infectivity can be controlled temporally and spatially. Attachment of a biotin derivative to an amphotropic murine retrovirus containing the *lacZ* reporter gene inhibited infectivity of the retrovirus vector while in transit. Upon reaching the target site, the biotin molecule was cleaved by exposure to light of wavelengths between 300–365 nm, allowing the vector to infect cells. Thus, infectivity can be inhibited and then activated under controlled conditions, making this vector construct a potentially safer and more efficient gene delivery vehicle.

## At last, a ligand for RXR

A long-sought ligand for the orphan retinoid-X receptor (RXR) been identified as a polyunsaturated fatty acid involved in brain development. RXR is a nuclear receptor that heterodimerizes with other proteins, such as the retinoic acid receptor, to function as a ligand-activated transcription factor. Although RXR is activated by the vitamin A metabolite *in vitro*, little is known about ligands that can activate RXR *in vivo*. In the 15 December issue of *Science*, Mata de Urquiza *et al.* report the isolation of an endogenous RXR ligand from mouse brain tissue. Mass spectrometry analysis revealed the ligand to be the polyunsaturated fatty acid DHA. The authors show that DHA specifically binds and activates RXR, but does not activate other similar receptors such as the retinoic acid receptor. DHA is expressed in mammalian brain during early stages of development, and has been shown to be required for brain maturation in rodents and people. DHA-deficient rats and humans develop learning defects, and the fatty acid is also known to influence metabolism and energy homeostasis. The authors suggest that DHA influences neural function through activation of the RXR signaling pathway.

## Fetal FISH

Researchers in Hong Kong have developed a non-invasive prenatal diagnostic test for Down syndrome. Fetal chromosomal abnormalities such as trisomy 21, the cause of Down syndrome, are currently detected through invasive procedures such as amniocentesis. In the 25 November issue of *The Lancet*, Poon *et al.* report that intact fetal cells are present in the plasma of pregnant women, and that these cells can be harvested and genetically analyzed. Using fluorescent *in situ* hybridization (FISH), the authors were able to detect the presence (picture) or absence of fetal trisomy 21 in fetal cells isolated from ten maternal plasma samples. These results are surprising, as plasma was believed to be acellular, although fetal DNA has been previously detected in maternal blood. The authors were also able to use the test to determine the sex of the fetuses as early as the end of the first trimester of pregnancy. All results were confirmed by karyotypic analysis of amniotic fluid. Ultimately, with further technical refinements, prenatal diagnosis by maternal plasma DNA analysis may be a safe approach for detecting genetic defects and chromosomal abnormalities.



## Power beads

Forget healing crystals—drug-releasing beads may be the next therapeutic delivery method. In the January issue of *Nature Biotechnology*, two studies describe the creation of a protein-producing matrix by mixing genetically-engineered kidney epithelial cells with a copolymer derived from seaweed. This mixture forms a beadlike matrix that allows free exchange of proteins, nutrients and oxygen. Read *et al.* and Joki *et al.* created encapsulated cells that constitutively overexpress endostatin, an anti-angiogeneic protein fragment that is currently being tested in clinical trials as an anti-cancer drug. Read *et al.* report that intracerebral implantation of these cells prevents tumor formation and growth in the brains of immunocompetent rats, while Joki *et al.* report that the implanted capsules reduce the growth of existing tumors by 70%. Studies have shown that continuous administration improves endostatin efficacy in mice, but would require patients to receive frequent injections or carry a delivery apparatus. The encapsulated cells survive and maintain endostatin production for at least four months after intracerebral implantation. They also exclude inflammatory cells, protecting the cells from rejection. These beads may be developed as a simplified method to continuously deliver anti-angiogenics and other therapeutic proteins to people.

## Diabetes signals

Two studies published in recent issues of *Nature* shed light on the signal transduction pathways underlying Type II diabetes mellitus. In the 14 December issue, Hart *et al.* report that pancreatic β cells express fibroblast growth factor receptors and ligands. Transgenic mice that produce a mutant form of the FGF receptor FGFR1c developed a phenotype resembling type II diabetes in humans, including fewer β cells, deficits in glucose homeostasis, and impaired insulin processing. The homeobox gene Ipf1 has been genetically linked to diabetes and the authors show that this gene regulates FGFR1c expression. Thus, the FGF pathway may mediate the nutritional and mitogenic control of β-cell expansion and function, and future studies should determine whether aberrant FGF signaling also contributes to human diabetes. In a second study published in the 21/28 December issue, Pende *et al.* show that mice deficient in S6 kinase (S6K1), a member of the PI3-kinase signaling pathway, develop a phenotype resembling malnutrition-induced type II diabetes. S6K1-deficient mice develop hypoinsulinemia and glucose intolerance, due to a decrease in β-cell size and decreased insulin secretion. Thus, S6K is involved in glucose homeostasis, and may underlie the link between early malnutrition and diabetes.

**Contributions by Kristine Novak, Karen Birmingham and Bernd Pulverer**

© 2001 Nature Publishing Group http://medicine.nature.com

studies with a stable isotope of magnesium (Mg-26) have revealed brand-new information about the magnesium-transport characteristics of smaller tissue structures in the kidney. These studies have opened new avenues of research.

Chandra said that numerous areas of cancer research may benefit from the application of this technique. It can be used to verify the anticancer potential of a drug by locating it in the cell and providing a comparison of its accumulation in normal and cancerous cells. The technique reveals changes in very basic cellular chemical composition (potassium, sodium and calcium levels). This allows the deeper study of cytotoxic actions of other anticancer drugs. Chandra added that the isotopic discrimination of the technique can also be used to study the location of molecules inside a cell by using molecules that have been modified to contain isotopic labels. This clears the way for studying the uptake and location of a wide variety of molecules or their metabolites inside a cell.

"The most interesting part of using [secondary ion mass spectrometry] for biological studies is that the technique is revealing a truthful location of elements and isotopes inside the cell. Even now we know so little about fundamental questions such as what is the role of calcium in cell division and why do cancer cells have abnormal calcium signaling. The application of this new technology may prove to be important in understanding these questions." □

*Richard Gaughan*

# Light-activated vector delivers therapeutic genes on target

BOSTON — Gene therapy is a medical technique that offers the possibility of directing the body's own mechanisms to repair or rebuild damaged cellular structures and functions. For example, if healthy heart cells could be triggered to replace old, damaged blood vessels with new ones, the resulting revascularization could provide significant improvement in heart function.

Delivering the genes is the key. Therapeutically useful genes can be delivered using retroviruses, which carry their genetic information in RNA and produce DNA in the cells they infect. The retroviruses can be encapsulated in glycoprotein envelopes, which are sugar-protein molecules. Genetic manipulation of these envelopes can target them biochemically toward specific cell surface structures, but the modifications required are often unstable, ineffective or even detrimental to the efficiency of the viral infection mechanism.

Dr. Mark Pandori and Dr. Takeshi Sano, researchers at Beth Israel Deaconess Medical Center of Harvard Medical School, have developed a strategy for localizing the delivery of gene therapeutic agents. They modify the envelope protein genetically, rather than for a physical reaction, adding light-sensitive infectivity inhibitors that are unlocked by long-wavelength UV radiation. The glycoprotein envelope thus keeps the retrovirus from infecting any cells until it is irradiated and opened.

The scientists surrounded a well-characterized retroviral vector with a modification reagent constructed from a biotin derivative. The vector, derived from amphotropic Moloney murine leukemia virus, carries a bacterial lacZ gene that turns blue when stained with a specific agent. The viral infectivity can then be easily evaluated because the nuclei of stained infected cells will turn blue. The biotin reagents link to components of the retrovirus, primarily those on the viral envelope glycoprotein. When the reagent is attached to the retroviral envelope, it inhibits the infectivity of the virus. But when exposed to UV light of 300 to 365 nm, the biotin derivative cleaves, restoring the conjugate protein to its original, unmodified form. The retrovirus has its infectivity restored.

Modified retroviral vectors were introduced into cultures of D-17, a strain of cancerous dog cells. Infectivity of cultures kept in the dark was extremely low, while those exposed to 365-nm light for at least three minutes exhibited more than 30 times the dark-culture infectivity. "The key to this work," said Sano, director of the Center for Molecular Imaging Diagnosis and Therapy at Beth Israel Deaconess, "is that the infectivity of retroviral vectors is made externally controllable by light."

Additional tests confirmed that the phenomenon of light-mediated infectivity activation involves the inactivation and subsequent reactivation of the function of the viral envelope glycoprotein. For some of those tests, modified retroviral vectors were irradiated prior to introduction into the cell cultures. Infectivity of the modified, but dark, retroviruses was extremely low. The infectivity increased after two to six minutes of irradiation but decreased when irradiation continued beyond eight minutes. This may be because of additional damage to the virus from shorter-wavelength UV light present in the lamp.

The treatment conditions developed for efficient infection of the D-17 cell line may not be appropriate for all cell lines. Although a number of human cell lines behave similarly, the levels of inactivation varied from line to line, suggesting that conditions may need to be tailored for specific cellular targets.

Pandori and Sano acknowledge that other difficulties lie ahead. For example, for in vivo applications, Sano said, "the challenge would be whether one can manipulate light beams three-dimensionally with sufficient intensities at target sites in the body. If this could be done, our system would be enormously useful for a variety of in vivo gene transfer applications where the timing and/or locations of the delivery of transgenes must be controlled precisely."

Although the technique already provides a valuable research tool, development is continuing. "For example," he said, "our system could be used if one wants to control the timing and/or location of gene transduction for in vitro systems or in experimental animals. ... First, we are refining this strategy. Second, we are applying this strategy to other viral systems, such as those derived from adenovirus, adeno-associated virus and herpes simplex virus. Third, we are developing in vivo gene transfer applications, such as gene therapy and tissue engineering."

Pandori and Sano believe that this is one of the few examples where the fundamental functions of complex biological assemblies could be controlled or switched by external signals. □

*Richard Gaughan*